サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784173

スルホンアミドの世界市場

Sulphonamides

出版日
ページ情報
英文 291 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
スルホンアミドの世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 291 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

スルホンアミドの世界市場は2030年までに1億6,250万米ドルに達する見込み

2024年に1億2,590万米ドルと推定されるスルホンアミドの世界市場は、2024年から2030年にかけてCAGR 4.3%で成長し、2030年には1億6,250万米ドルに達すると予測されます。本レポートで分析されているセグメントの一つである経口剤は、CAGR4.9%を記録し、分析期間終了時には1億250万米ドルに達すると予測されています。局所セグメントの成長率は、分析期間中CAGR 3.6％と推定されます。

米国市場は3,430万米ドルと推定、中国はCAGR 8.0％で成長すると予測

米国のスルホンアミド市場は、2024年には3,430万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに3,360万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは8.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.7％と3.4％と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界のスルホンアミド市場- 主要動向と促進要因のまとめ

高度抗生物質時代においてもスルホンアミドが重要なのはなぜか？

新しいクラスの抗生物質が出現しているにもかかわらず、スルホンアミドは、特にその広域スペクトル活性、手頃な価格、実績のある臨床歴により、世界の抗菌剤治療の基礎的要素であり続けています。最も初期の合成抗菌薬であるスルホンアミドは、尿路感染症や呼吸器疾患から眼感染症や髄膜炎に至るまで、細菌感染症の治療に広く使用されてきました。スルホンアミドの継続的な意義は、その薬理学的汎用性と、特に新薬へのアクセスが限られている地域において、特定の細菌株に対する永続的な有効性の両方にあります。さらに、スルホンアミドはトリメトプリムのような他の抗菌薬との合剤で使用されることが一般的で、治療効果を高め、耐性菌の開発を抑制します。スルホンアミドの使用は、ヒトの薬に限定されるものではありません。スルホンアミドは、特に家畜や家禽などの獣医学的用途においても重要であり、細菌感染を管理し、食の安全に影響を与える可能性のある病気の発生を予防するのに役立ちます。さらに、スルホンアミドは費用対効果に優れているため、特に先進的な治療法へのアクセスが制限されている中低所得国において、公衆衛生プログラムに不可欠なツールとなっています。ヒトと動物の健康に応用できることから、安定した需要のベースラインが確保され、世界のヘルスケア・システムにおける長期的な有用性がさらに強調されています。

抗菌薬耐性（AMR）はスルホンアミド市場にどのような影響を与えているか？

抗菌薬耐性（AMR）の世界の増加は、スルホンアミド市場に二重の影響を与えています。一方では、一般的な病原菌の耐性化が、スルホンアミドを含む古い抗生物質の再評価を促しています。一部の臨床現場、特に資源に乏しい国々では、耐性菌の増加を防ぐために治療法をローテーションしたり併用したりする抗菌薬スチュワードシップ戦略の一環として、スルホンアミドが治療プロトコールに再び導入されつつあります。一方、AMRに対する懸念の高まりから、ヒトと獣医の両医療における抗生物質の使用に関する規制がより厳しくなり、スルホンアミドの処方や投与方法に影響を与えています。サーベイランスプログラムでは、抗生物質の使用状況を詳細に追跡することが要求されるようになり、環境暴露や交差耐性を制限するために、農業におけるスルホンアミドの予防的使用を制限したり、段階的に廃止したりする動きを見せている国もあります。しかし、スルホンアミドは慎重に使用すれば、抗菌薬の重要なツールであることに変わりはありません。標的薬剤放出やナノ粒子キャリアなど、新しい製剤やデリバリーメカニズムに関する調査も、有効性の向上と耐性リスクの低減を目指して進行中です。このように進化する状況の中で、市場情勢は陳腐化ではなく、世界のAMR緩和の取り組みに沿った、管理されたエビデンスに基づくアプリケーションの必要性によって再構築されつつあります。

市場の安定性において、動物用医薬品と農業用医薬品はどのような役割を果たすのか？

動物用医薬品と農業用医薬品は、スルホンアミドの世界の需要を維持する上で重要な役割を果たしています。動物用医薬品では、スルホンアミドはコクシジウム症、サルモネラ症、呼吸器疾患などの家畜、家禽、水産養殖における細菌感染症の治療に広く使用されています。幅広いスペクトラム活性を持ち、比較的安価であるため、集約的な畜産システム、特に畜産が急増している新興市場での大量治療プロトコールに最適です。さらに、スルホンアミドはしばしば薬用飼料や水に配合されるため、大規模な牛群や群れ全体に効率的に投与することができます。これらの化合物は、疾病負担を軽減し、食用動物の生産性を向上させるための予防衛生プログラムにも採用されており、生産者に直接的な経済効果をもたらしています。しかし、農業におけるスルホンアミドの広範な使用は、食品中の残留抗生物質や環境汚染に対する懸念の高まりの下で、現在精査されています。欧州連合（EU）、米国、中国を含む各地域の規制機関は、食品の安全性を確保するため、残留モニタリングや最大残留基準値（MRL）の枠組みを導入しています。こうした規制は過剰使用を抑制する一方で、残留物質を含まない製剤の技術革新や、的を絞った治療を導くための獣医学的診断法の改善を促しています。世界のタンパク質消費量が特にアジアとアフリカで増加するにつれて、スルホンアミドの動物用アプリケーションは引き続き市場安定の重要な促進要因になると予想されます。

今日のスルホンアミドの世界の需要と戦略的関心の原動力は？

スルホンアミド市場の成長は、治療アクセス、産業ニーズ、疫学パターン、コスト効率に関連するいくつかの要因によって牽引されています。主な要因のひとつは、開発途上地域における細菌感染症が引き続き高い負担となっていることであり、スルホンアミドは手頃な価格で広く入手できるため、第一選択薬または第二選択薬として使用されています。WHOやユニセフのような組織が必須医薬品への公平なアクセスを重視するようになったことは、世界の保健政策におけるスルホンアミドの役割を強化しています。さらに、人口の増加と動物性タンパク質に対する需要の増加は、特に急速に発展している新興経済諸国において、動物用抗菌薬の必要性を拡大しています。スルホンアミドは製造が比較的容易で保存期間が長いため、ジェネリック医薬品メーカーにとって魅力的であり、幅広い流通と競争力のある価格設定が確保されています。研究面では、旧薬の再利用に再び注目が集まっており、特に顧みられない熱帯病や耐性病原体の問題において、スルホンアミドが再び注目されています。さらに、スルホンアミドの併用療法、外用治療、小児用製剤への統合により、その臨床的汎用性が拡大しています。ヒトと動物の健康、規制の変化、新たな治療戦略など、これらの力学が世界の需要を維持し、スルホンアミドを抗菌薬市場の永続的な構成要素として位置づけています。

セグメント

投与経路（経口剤、局所剤、その他）;用途（皮膚感染症、胃腸管感染症、尿路感染症、呼吸器管感染症、その他）

調査対象企業の例

  • AA Pharma Inc.
  • Abbott Laboratories
  • Akorn Operating Company LLC
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Clinivex
  • Creative Biolabs Laboratories
  • Dishman Carbogen Amcis Ltd
  • Dr. Reddy's Laboratories
  • Elam Pharma
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Lexine Technochem Pvt. Ltd
  • LGC Standards
  • Manus Aktteva Biopharma LLP
  • Monarch Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stratechem（I）Pvt. Ltd
  • Sun Pharmaceutical Industries Ltd
  • TCI America
  • Teva Pharmaceutical Industries Ltd
  • Valeo Pharma Inc.
  • Viatris Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33075

Global Sulphonamides Market to Reach US$162.5 Million by 2030

The global market for Sulphonamides estimated at US$125.9 Million in the year 2024, is expected to reach US$162.5 Million by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$102.5 Million by the end of the analysis period. Growth in the Topical segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$34.3 Million While China is Forecast to Grow at 8.0% CAGR

The Sulphonamides market in the U.S. is estimated at US$34.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$33.6 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Sulphonamides Market - Key Trends & Drivers Summarized

Why Are Sulphonamides Still Relevant in the Era of Advanced Antibiotics?

Despite the emergence of newer classes of antibiotics, sulphonamides remain a foundational element in global antimicrobial therapy, particularly due to their broad-spectrum activity, affordability, and proven clinical history. As some of the earliest synthetic antimicrobials, sulphonamides have been widely used to treat bacterial infections ranging from urinary tract infections and respiratory illnesses to eye infections and meningitis. Their continued relevance stems from both their pharmacological versatility and enduring efficacy against certain strains of bacteria, especially in regions with limited access to newer drugs. Moreover, sulphonamides are commonly used in fixed-dose combinations with other antimicrobials like trimethoprim to enhance therapeutic outcomes and reduce resistance development. Their use is not limited to human medicine-sulphonamides are also critical in veterinary applications, particularly in livestock and poultry, where they help manage bacterial infections and prevent disease outbreaks that could impact food safety. In addition, the cost-effectiveness of sulphonamides makes them an indispensable tool in public health programs, especially in low- and middle-income countries where access to more advanced therapies may be constrained. Their dual application across human and animal health ensures a stable baseline of demand, further underscoring their long-standing utility in global healthcare systems.

How Is Antimicrobial Resistance (AMR) Influencing the Sulphonamides Market?

The global rise in antimicrobial resistance (AMR) is having a dual impact on the sulphonamides market. On one hand, increasing resistance among common pathogens has prompted a re-evaluation of older antibiotics, including sulphonamides, which may still retain effectiveness against specific bacterial strains. In some clinical settings, particularly in resource-limited countries, sulphonamides are being reintroduced into treatment protocols as part of antimicrobial stewardship strategies that rotate or combine therapies to prevent resistance build-up. On the other hand, growing concerns over AMR have led to more stringent regulatory controls on the use of antibiotics in both human and veterinary medicine, influencing how sulphonamides are prescribed and administered. Surveillance programs now require detailed tracking of antibiotic usage, and some countries are moving to restrict or phase out prophylactic use of sulphonamides in agriculture to limit environmental exposure and cross-resistance. However, when used judiciously, sulphonamides remain an important tool in the antimicrobial arsenal. Research into novel formulations and delivery mechanisms-such as targeted drug release and nanoparticle carriers-is also underway to improve efficacy and reduce resistance risks. In this evolving landscape, the market for sulphonamides is being reshaped not by obsolescence, but by the need for controlled, evidence-based applications that align with global AMR mitigation efforts.

What Role Do Veterinary and Agricultural Applications Play in Market Stability?

Veterinary and agricultural uses play a significant role in maintaining the global demand for sulphonamides. In animal health, sulphonamides are widely used to treat bacterial infections in livestock, poultry, and aquaculture, including conditions like coccidiosis, salmonellosis, and respiratory diseases. Their broad-spectrum activity and relatively low cost make them ideal for mass treatment protocols in intensive farming systems, especially in emerging markets where livestock production is increasing rapidly. Moreover, sulphonamides are often included in medicated feed or water, allowing for efficient delivery across large herds or flocks. These compounds are also employed in preventive health programs to reduce disease burden and improve productivity in food animals, which has a direct economic impact for producers. However, the extensive use of sulphonamides in agriculture is now being scrutinized under growing concerns about antibiotic residues in food products and environmental contamination. Regulatory agencies across regions-including the European Union, the United States, and China-have introduced residue monitoring and maximum residue limit (MRL) frameworks to ensure food safety. While such regulations may restrain overuse, they are also prompting innovation in residue-free formulations and improved veterinary diagnostics to guide targeted treatment. As global protein consumption rises, particularly in Asia and Africa, the veterinary application of sulphonamides is expected to remain a key driver of market stability.

What’s Driving Global Demand and Strategic Interest in Sulphonamides Today?

The growth in the sulphonamides market is driven by several factors related to therapeutic access, industrial need, epidemiological patterns, and cost-efficiency. One of the key drivers is the continued high burden of bacterial infections in developing regions, where sulphonamides serve as first-line or second-line therapy due to their affordability and widespread availability. The growing emphasis on equitable access to essential medicines by organizations such as the WHO and UNICEF reinforces the role of sulphonamides in global health policies. Additionally, population growth and the increasing demand for animal protein are expanding the need for veterinary antimicrobials, particularly in fast-developing agricultural economies. The relative ease of manufacturing and long shelf life of sulphonamides make them attractive to generic pharmaceutical producers, ensuring broad distribution and competitive pricing. On the research front, renewed interest in repurposing older drugs has brought sulphonamides back into focus, especially in the context of neglected tropical diseases and resistant pathogens. Furthermore, the integration of sulphonamides into combination therapies, topical treatments, and pediatric formulations is expanding their clinical versatility. Collectively, these dynamics-spanning human and animal health, regulatory shifts, and emerging therapeutic strategies-are sustaining global demand and positioning sulphonamides as an enduring component of the antimicrobial market.

SCOPE OF STUDY:

The report analyzes the Sulphonamides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Topical, Others); Application (Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AA Pharma Inc.
  • Abbott Laboratories
  • Akorn Operating Company LLC
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cadila Pharmaceuticals Ltd
  • Cipla Ltd
  • Clinivex
  • Creative Biolabs Laboratories
  • Dishman Carbogen Amcis Ltd
  • Dr. Reddy's Laboratories
  • Elam Pharma
  • F. Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Lexine Technochem Pvt. Ltd
  • LGC Standards
  • Manus Aktteva Biopharma LLP
  • Monarch Pharmaceuticals
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stratechem (I) Pvt. Ltd
  • Sun Pharmaceutical Industries Ltd
  • TCI America
  • Teva Pharmaceutical Industries Ltd
  • Valeo Pharma Inc.
  • Viatris Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Sulphonamides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • High Prevalence of Infectious Diseases in Developing Regions Propels Demand for Cost-Effective Antimicrobials
    • Combination Therapies and Fixed-Dose Formulations Strengthen the Business Case for Sulphonamide Use
    • Veterinary Applications in Livestock and Poultry Expand the Addressable Market in Animal Health
    • Re-Evaluation of Older Drugs Amid Antimicrobial Resistance Drives Renewed Use in Clinical Practice
    • Access to Essential Medicines Frameworks Sustain Sulphonamide Use in Public Health Programs
    • Long Shelf Life and Ease of Production Generate Competitive Advantage for Generic Manufacturers
    • Use in Preventive Animal Health Programs Drives Market Adoption in Intensive Farming Operations
    • Growing Application in Combination Antimalarial and Antibacterial Therapies Expands Formulation Potential
    • Surveillance of Antimicrobial Resistance Creates Demand for Controlled, Targeted Usage Protocols
    • Rising Research in Neglected Tropical Diseases Positions Sulphonamides for New Therapeutic Roles
    • Expanding Veterinary Infrastructure and Pet Ownership Trends Drive Growth in Companion Animal Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sulphonamides Market Analysis of Annual Sales in US$ for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sulphonamides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Skin Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Skin Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gastro Intestinal Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gastro Intestinal Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Gastro Intestinal Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Urinary Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Urinary Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory Tract Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Respiratory Tract Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Sulphonamides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Sulphonamides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Sulphonamides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Sulphonamides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Sulphonamides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Sulphonamides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Sulphonamides by Administration Route - Oral, Topical and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Sulphonamides by Administration Route - Percentage Breakdown of Value Sales for Oral, Topical and Other Administration Routes for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Sulphonamides by Application - Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Sulphonamides by Application - Percentage Breakdown of Value Sales for Skin Infections, Gastro Intestinal Tract Infections, Urinary Tract Infections, Respiratory Tract Infections and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION